Zepatier (Elbasvir/Grazoprevir) Patent Expiration, LOE Window & CMS Spending

Zepatier (Elbasvir/Grazoprevir) by Merck & Co.: FDA Orange Book core substance LOE 2031-05-04, 0 AB generics, $497K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN208261 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-05-04
Last Listed Patent or Exclusivity Date2031-05-04
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$497K
2024 Medicare Part D Spend$224K
2024 Medicaid Spend$274K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.